About verastem inc - VSTM
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
VSTM At a Glance
Verastem, Inc.
117 Kendrick Street
Needham, Massachusetts 02494
| Phone | 1-781-292-4200 | Revenue | 30.91M | |
| Industry | Biotechnology | Net Income | -209,471,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 209.14% | |
| Fiscal Year-end | 12 / 2026 | Employees | 102 | |
| View SEC Filings |
VSTM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 17.308 |
| Price to Book Ratio | 10.493 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.463 |
| Enterprise Value to Sales | 13.497 |
| Total Debt to Enterprise Value | 0.209 |
VSTM Efficiency
| Revenue/Employee | 303,078.431 |
| Income Per Employee | -2,053,637.255 |
| Receivables Turnover | 3.355 |
| Total Asset Turnover | 0.178 |
VSTM Liquidity
| Current Ratio | 3.091 |
| Quick Ratio | 3.066 |
| Cash Ratio | 2.837 |
VSTM Profitability
| Gross Margin | 82.862 |
| Operating Margin | -550.33 |
| Pretax Margin | -677.593 |
| Net Margin | -677.593 |
| Return on Assets | -120.393 |
| Return on Equity | -1,480.151 |
| Return on Total Capital | -145.097 |
| Return on Invested Capital | -277.642 |
VSTM Capital Structure
| Total Debt to Total Equity | 152.401 |
| Total Debt to Total Capital | 60.381 |
| Total Debt to Total Assets | 35.371 |
| Long-Term Debt to Equity | 142.193 |
| Long-Term Debt to Total Capital | 56.336 |